Abstract
Type 2 diabetes is a chronic disease characterized by impaired insulin action, progressive β-cell dysfunction as well as abnormalities in pancreatic α-cell function and postprandial substrate delivery. These pathophysiologic defects result in both persistent and progressive hyperglycemia, resulting in increased risk of both microvascular and cardiovascular complications. Traditional treatments for type 2 diabetes have focused on impaired insulin secretion and insulin resistance. These strategies are typically used in a stepwise manner: employing oral glucose lowering agents, followed by insulin therapy. This traditional approach fails to address the progressive decline in β-cell function. Moreover, these therapies are often associated with weight gain in overweight or obese patients with type 2 diabetes. Both exogenous insulin and insulin secretagogues are associated with an increased risk of hypoglycemia. Recently, new treatments that leverage the glucoregulatory effects of incretin hormones, such as glucagon-like peptide-1 have been introduced. Both incretin mimetics and DPP-4 inhibitors address both the underlying pathophysiology and overcome several of the limitations of established therapies by providing improvements in glycemia, and control of body weight with minimal risk of hypoglycemia.
Keywords: Body weight, DPP-4 inhibitor, Glycemia, Incretin mimetic, Type 2 diabetes
Current Diabetes Reviews
Title: Emerging Incretin-Based Therapies for Type 2 Diabetes: Incretin Mimetics and DPP-4 Inhibitors
Volume: 4 Issue: 2
Author(s): Anthony Stonehouse, Ted Okerson, David Kendall and David Maggs
Affiliation:
Keywords: Body weight, DPP-4 inhibitor, Glycemia, Incretin mimetic, Type 2 diabetes
Abstract: Type 2 diabetes is a chronic disease characterized by impaired insulin action, progressive β-cell dysfunction as well as abnormalities in pancreatic α-cell function and postprandial substrate delivery. These pathophysiologic defects result in both persistent and progressive hyperglycemia, resulting in increased risk of both microvascular and cardiovascular complications. Traditional treatments for type 2 diabetes have focused on impaired insulin secretion and insulin resistance. These strategies are typically used in a stepwise manner: employing oral glucose lowering agents, followed by insulin therapy. This traditional approach fails to address the progressive decline in β-cell function. Moreover, these therapies are often associated with weight gain in overweight or obese patients with type 2 diabetes. Both exogenous insulin and insulin secretagogues are associated with an increased risk of hypoglycemia. Recently, new treatments that leverage the glucoregulatory effects of incretin hormones, such as glucagon-like peptide-1 have been introduced. Both incretin mimetics and DPP-4 inhibitors address both the underlying pathophysiology and overcome several of the limitations of established therapies by providing improvements in glycemia, and control of body weight with minimal risk of hypoglycemia.
Export Options
About this article
Cite this article as:
Stonehouse Anthony, Okerson Ted, Kendall David and Maggs David, Emerging Incretin-Based Therapies for Type 2 Diabetes: Incretin Mimetics and DPP-4 Inhibitors, Current Diabetes Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339908784220705
DOI https://dx.doi.org/10.2174/157339908784220705 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemoenzymatic Synthesis of Carbohydrates as Antidiabetic and Anticancer Drugs
Current Topics in Medicinal Chemistry The Role of T-Type Calcium Channels in Peripheral and Central Pain Processing
CNS & Neurological Disorders - Drug Targets Evaluation of the Possible Contribution of Antioxidants Administration in Metabolic Syndrome
Current Pharmaceutical Design Lab-scale Preparation of Recombinant Human Insulin-like Growth Factor-1 in <i>Escherichia coli</i> and its Potential Safety on Normal Human Lung Cell Line
Recent Patents on Biotechnology Mechanisms of Melatonin in Alleviating Alzheimer’s Disease
Current Neuropharmacology Antiobesity Effect of Biochanin-A: Effect on Trace Element Metabolism in High Fat Diet-Induced Obesity in Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Resolvins: Endogenously-Generated Potent Painkilling Substances and their Therapeutic Perspectives
Current Neuropharmacology Drug Repurposing: An Emerging Tool for Drug Reuse, Recycling and Discovery
Current Drug Research Reviews In Vitro Investigation Demonstrates IGFR/VEGFR Receptor Cross Talk and Potential of Combined Inhibition in Pediatric Central Nervous System Atypical Teratoid Rhabdoid Tumors
Current Cancer Drug Targets Construction of a γ-Butyrolactone Moiety: A Facile Synthesis of 3β- Hydroxy-5,6-Dihydro-17β -Methoxy-Pregnan-21,16α-Carbalactone - a New D-Ring Fused Steroidal γ-Butyrolactone from an Abundant 20- Oxopregnane using Metal Mediated Halogenation as the Key Step
Letters in Organic Chemistry Chronic Inflammation: Role of Adipose Tissue and Modulation by Weight Loss
Current Diabetes Reviews Cardio-Vascular Risks Associated with Clozapine Treatment
Current Psychiatry Reviews The Pleiotropic Effects of ARB in Vascular Endothelial Progenitor Cells
Current Vascular Pharmacology The Use of Stem Cells in Regenerative Medicine for Parkinson’s and Huntington’s Diseases
Current Medicinal Chemistry Subject Index To Volune 2
Current Cancer Therapy Reviews Type-3c Diabetes Mellitus, Diabetes of Exocrine Pancreas - An Update
Current Diabetes Reviews Animal Models of Addiction: Fat and Sugar
Current Pharmaceutical Design Lentinus edodes: A Macrofungus with Pharmacological Activities
Current Medicinal Chemistry Elucidation of Malaria on Metabolic Activities During Pregnancy
Current Women`s Health Reviews Molecular Imprinted Polymer Based Impedimetric Sensor for Trace Level Determination of Digoxin in Biological and Pharmaceutical Samples
Current Analytical Chemistry